Abstract
Taxol® is a novel chemotherapeutic agent that has produced substantial responses in early clinical studies [1]. Taxol has excellent activity in a number of malignancies based on recently completed clinical trials, including a 30% response rate in platinum-refractory ovarian cancer patients [2–5]. We are currently conducting trials of dose-intense taxol with granulocyte colony stimulating factor (G-CSF) support in relapsed or refractory ovarian cancer patients. Such dose intensification produces a major response rate in 50% of patients with this disease [6]. Taxol was supplied in 5 ml ampules (6 mg/ml) in polyethoxylated castor oil (Cremophor EL) 50% and dehydrated alcohol and the dose was diluted in either 0.9% sodium chloride or 5% dextrose at concentrations of 0.6 to 1.2 mg/ml. We have noted 3 patients with previously unreported cutaneous manifestations which we believe are taxol related and also report our overall complication rate with the administration of taxol by peripheral intravenous lines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chabner BA: Taxol. Principles and practice of oncology updates 5:1–10, 1991
Sarosy GA, Kohn EC, Stone DA, Rothenburg M, Jacob J, Adamo D, Cunnion RE, Reed E: Phase I study of taxol and G-CSF in patients with refractory ovarian cancer. J Clin Oncol 10:1165–1170, 1992
Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in malignant melanoma. J Clin Oncol 5:1232–1239, 1987
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279, 1989
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Instil 83:1797–1805 1992
Sarosy GA, Kohn EC, Link CJ, Adamo D, Davis P, Ognibene F, Goldspiel B, Christian M, Reed E: Taxol dose intensification in patients with recurrent ovarian cancer (Abstract). Proc Am Soc Clin Oncol 11:716, 1992
Wintraub BU, Stern RS, Arndt KA: Cutaneous reactions to drugs. In: Fitzpatric TB (ed) Dermatology in General Medicine. McGraw-Hill Book Co, New York, 1987, pp 1353–63
James WD, Odum RB: Chemotherapy-induced transverse white lines in the fingernails. Arch Dermatol 119:334–335, 1983
Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Amer Acad Dermatol 9:645–663, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Link, C.J., Sarosy, G.A., Kohn, E.C. et al. Cutaneous manifestations of taxol® therapy. Invest New Drugs 13, 261–263 (1995). https://doi.org/10.1007/BF00873811
Issue Date:
DOI: https://doi.org/10.1007/BF00873811